Sitryx Therapeutics Ltd. has disclosed nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.
The σ2 receptor (σ2R) has been recently identified as transmembrane protein 97 (TMEM97), and ligands of σ2R/TMEM97 have previously shown the ability to alleviate mechanical hypersensitivity in mouse models of neuropathic pain.
Overexpression of the enhancer of zeste homolog 2 (EZH2) has been found in multiple cancer types, such as myeloma, lymphoma, prostate, breast, lung or kidney cancer.
CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.
Intravacc BV has been awarded funding for up to $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) for the development of a preventive vaccine against Neisseria gonorrhoeae (NG), the bacterium that causes gonorrhea.
Researchers from Shenzhen Salubris Pharmaceuticals Co. Ltd. have published preclinical data for the angiotensin receptor neprilysin (ARN) inhibitor S-086, currently in clinical development for the treatment of hypertension.
There are several factors that induce cirrhosis. During cirrhosis, there is an increased intrahepatic resistance to blood flow, leading to portal hypertension, among others, where portal vein pressure is increased.
Toleranzia AB has completed a pivotal toxicology study designed to determine the potential toxicity of TOL-2, a tolerance-inducing recombinant protein being developed for the treatment of myasthenia gravis, when given intravenously for 10 days.
Although treatment outcomes have improved in metastatic melanoma since the use of immune checkpoint blockade (ICB), it still remains a medical challenge. Melanoma cells are thought to adapt several phenotypic states, such as mesenchymal-like state (MES), which may modulate their sensitivity to therapy. An international team of researchers has now investigated the mechanisms behind melanoma cells’ resistance to ICB.
Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate antitumoral immune responses, but may also induce toxicity, such as colitis, a common immune-related adverse event that can lead to treatment discontinuation.
RSS
